MapLight Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that it entered into a Sales Agreement with Leerink Partners LLC to offer and sell up to $100,000,000 of its common stock through an at-the-market equity program.

Key Highlights

  • Agreement date: The Sales Agreement with Leerink Partners LLC was entered into on November 16, 2026.
  • Maximum offering size: The company may sell common stock with an aggregate offering price of up to $100,000,000 under the ATM Prospectus.
  • Agent commission: Leerink Partners LLC will be entitled to a commission of up to 3.0% of the aggregate gross sales price per share sold.
  • Registration: The ATM Shares will be offered pursuant to a Registration Statement on Form S-3 filed by the company on November 16, 2026 (File No. 333-300071).
  • No obligation to sell: According to the filing, the company "has no obligation to sell any of the ATM Shares and may at any time suspend offers under the Agreement or terminate the Agreement."

MapLight Therapeutics Establishes At-the-Market Equity Facility with Leerink Partners

MapLight Therapeutics, Inc. (NASDAQ:MPLT), a Delaware-incorporated biopharmaceutical company headquartered at 800 Chesapeake Drive, Redwood City, California 94063, disclosed on November 16, 2026 that it entered into a Sales Agreement with Leerink Partners LLC under which it may, from time to time, offer and sell shares of its voting common stock, par value $0.0001 per share. The filing was signed by Christopher A. Kroeger, M.D., Chief Executive Officer.

According to the filing, sales of ATM Shares under the agreement may be made in transactions deemed to be "at the market offerings" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. The Agent is required to use "commercially reasonable efforts" to sell shares based on the company's instructions, and the company has provided the Agent with customary indemnification rights. The commission payable to Leerink Partners LLC is up to 3.0% of the aggregate gross sales price per share sold.

The company disclosed that the ATM Shares will be offered pursuant to the Registration Statement on Form S-3 filed on November 16, 2026, and the related ATM Prospectus forming part of that Registration Statement. The filing notes that this Form 8-K "shall not constitute an offer to sell or the solicitation of an offer to buy" ATM Shares in any state where such an offer or sale would be unlawful prior to registration or qualification. The company is identified in the filing as an emerging growth company.

What Was Disclosed

MapLight Therapeutics disclosed entry into an at-the-market sales agreement with Leerink Partners LLC on November 16, 2026, permitting the sale of up to $100,000,000 in common stock, subject to a commission of up to 3.0%, with no obligation to sell any shares.